Disability accessibility tool
+

News Releases

Latest News Releases

Keyword Search

9/21/23

Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

9/14/23

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

9/12/23

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

9/11/23

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

8/31/23

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

8/29/23

Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules

8/28/23

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

8/18/23

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

8/1/23

Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

7/11/23

Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors

7/11/23

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results

6/15/23

Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023

6/8/23

Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

6/2/23

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

5/19/23

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology

5/15/23

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society

5/12/23

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

5/3/23

Neurocrine Biosciences Reports First Quarter 2023 Financial Results

5/2/23

Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference

5/1/23

Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week

4/12/23

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results

3/21/23

Neurocrine Biosciences to Present at the Stifel 2023 CNS Days

3/9/23

Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning

3/9/23

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference

3/8/23

Neurocrine Biosciences to Participate at Investor Conferences in March

3/3/23

Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting

2/7/23

Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference

2/6/23

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

1/17/23

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results

1/9/23

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

1/3/23

Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference